Oral fish oil positively influences nutritional-inflammatory risk in patients with hematological malignancies during chemotherapy with impact on long-term survival: a randomized clinical trial

Short-title (Running Head): Fish oil and hematological malignancies

Abstract

Background: Studies suggest ingestion fish oil (FO), a source of the omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), can reduce deleterious side-effects of chemotherapy. The aim of this randomized clinical trial was to evaluate the effect of supplementation with oral FO for nine weeks on nutritional parameters and inflammatory nutritional risk in patients with hematological malignancies during the beginning of the chemotherapy. Methods: Twenty-two patients with leukemia or lymphoma were randomized to the unsupplemented group (UG) (n=13) or supplemented group (SG) (n=9). SG received 2 g/day of fish oil for nine weeks. Nutritional status, serum acute-phase proteins, and plasma fatty acids were evaluated before (T0) and after (T1) the intervention period. Data were analyzed by two models; model 1 - data from all patients included in the study, and model 2 - data from UG patients with no increase in the proportions of EPA and DHA in plasma and data from SG patients showing, at least, a 100% increase in plasma EPA and DHA. Results: SG showed increased plasma proportion of EPA and DHA in both models. In model 2, C-reactive protein (CRP) and CRP/albumin ratio showed larger reductions in the SG. Overall long-term survival in both models (465 days after the start of the chemotherapy) was higher in the group ingesting fish oil (P<0.05). Conclusions: These findings indicate an improved nutritional-inflammatory risk and potential effects on long-term survival in patients with hematological malignancies supplemented with FO during the beginning of chemotherapy. Keywords: fish oil, n-3 PUFA, hematologic malignancies, nutritional status, leukemia and lymphoma.
**Introduction**

Hematologic malignancies belong to a heterogeneous group of hematologic diseases (13). Inflammation is now recognized to be an important component in cancer prognosis, with several inflammatory markers being in use to monitor disease progression and prognosis (49). One of the main strategies used to treat hematological malignancies is chemotherapy. The treatment aims to destroy neoplastic cells, but also affects healthy cells, like cells of the gastrointestinal tract (2). Adverse effects caused by antineoplastic therapy include giddiness, nausea, vomiting, mucositis, dysphagia, diarrhea, and changes in taste and smell perception (7). Such adverse effects are linked to metabolic and nutritional losses and subsequent deterioration in the quality of life (39, 15).

Dietary fatty acids (FAs) have profound physiological implications (28). Studies suggest that ingestion of n-3 polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) found in fish oil, can be beneficial to cancer treatment by preserving nutritional status (17), decreasing inflammatory markers (e.g. positive acute-phase proteins) (33), and increasing survival (31). However, studies using fish oil supplementation in hematological malignancies are scarce, and there is no clear information regarding indication to use or not such nutritional strategy in these patients.

The aim of this study was to evaluate the effect of oral supplementation with 2 g/day of fish oil (a source of EPA and DHA) for nine weeks on nutritional parameters and inflammatory status in newly diagnosed patients with hematological malignancies starting chemotherapy. Overall survival to 465 days from the start of fish oil supplementation was a secondary outcome. We hypothesized that patients diagnosed with hematological malignancies would show a reduction in overall nutritional inflammatory risk and improved survival when ingesting fish oil.

**Experimental Methods**

**Subjects**

Patients with hematological malignancies assisted at the Ambulatory and Hematology Clinical Center of the University Hospital of Santa Catarina - Florianópolis, Santa Catarina, Brazil, from November 2012 to December 2013 participated in this randomized clinical trial (RCT). The eligibility criteria were: age ≥
18 years, histopathological diagnosis of leukemia or lymphoma and chemotherapy treatment indication. Exclusion criteria were: being in palliative care, taking statins or anti-inflammatory drugs, being allergic to fish and fish derivatives, being unable to perform oral ingestion of food, having received chemotherapy previously, being pregnant, ingesting fish oil or other n-3 PUFA supplements in the six months before study initiation. A non-probabilistic convenience sample was defined by time saturation.

The diagnosis and disease staging were established according to routine biopsy, immunophenotyping, cytogenetics and immunohistochemistry, conducted by the University Hospital Pathology Division.

Study design

Eligible patients were randomly allocated into one of two groups: supplemented group (SG) and unsupplemented group (UG). Randomization was performed with the online tool: Research Randomizer (http://www.randomizer.org/). Odd numbers represented patients allocated to SG and even numbers allocated to UG. The study was conducted following guidelines in the Declaration of Helsinki (40). All procedures involving human patients were approved by the Research Ethics Committee of the local Institution. All participants signed a consent form. The trial is registered at www.ensaiosclinicos.gov.br, under the register RBR-7q6cqg.

The patients in the SG were instructed to ingest two capsules/day of fish oil (2 g/day in total) for nine weeks. This dose has been tested effectively in previous studies (28, 40, 41). Subjects were instructed to ingest capsules in a dose-fractionated form, about 20 to 30 minutes before lunch or dinner and accompanied by liquid. During the supplementation period, supplement intake was controlled by weekly phone calls (for non-hospitalized subjects) or daily contact in the hospital. Also, subjects were instructed to record capsules intake in a provided form. The supplementation started on the first day of the chemotherapy (T0). The UG did not receive any supplement.

Personal data, lifestyle information and weight loss in the previous six months were obtained by interview. Clinical data (hematologic malignant diagnosis, stage, other diseases and medication use) were obtained from patient records.

Dietary supplement
The fish oil supplement was in the form of gelatin capsules with 1,000 mg oil/capsule (Omega 3, Phytomare®, Governador Celso Ramos, SC, Brazil). The oil was extracted from salmon, mackerel, and sardines. Two fish oil capsules provided a total of 17 kilocalories, and 0.7 g saturated fatty acids, 0.5 g monounsaturated fatty acids, 0.8 g polyunsaturated fatty acids, and 4 mg of cholesterol. Two capsules provided a total of 610 mg of n-3 PUFAs (367 mg of EPA and 243 mg of DHA). Analysis of the fatty acid profile of the fish oil capsule, by high-performance liquid chromatography, was conducted and returned the following proportions (%) of the investigated fatty acids: EPA 25.06; DHA 14.58; palmitic 18.95; myristic 9.71; arachidonic < 1; palmitoleic 12.94; oleic 9.73; linoleic 2.99; stearic 5.76; α-linolenic < 1.

Anthropometric data

Weight and height were measured with an electronic platform scale with a coupled vertical stadiometer (Toledo®, Toledo Company of Brazil, São Bernardo do Campo, SP, Brazil). Usual weight was self-reported by the patient. Triceps skinfold (TS) was measured with a Compass Lange Skinfold Caliper® (Beta Technology Incorporated, Santa Cruz, California, USA) and mid-upper arm circumference (MUAC) was measured with an inelastic tape (TBW®, São Paulo, SP, Brazil). TS and AC were obtained from the arithmetic mean of three measures. All anthropometric measurements were made following standard techniques.

Blood collection

Blood samples (30 mL) were collected after approximately eight hours of fasting at two-time points: on the day prior to the first chemotherapy (baseline) and nine weeks later (week 9). Blood was collected into vacuum tubes (Vacutainer® System, BD Biosciences, Abingdon, UK) containing lithium-heparin. Plasma was prepared and stored at -80°C until thawing for determination of fatty acid profile. Blood was collected into separating gel tubes and serum isolated for determination of CRP and albumin concentrations.

Determination of hemogram, albumin and CRP concentration

Hemogram parameters were obtained from whole blood using an automated method (Sysmex Xe-2100, Roche®, Kobe, Japan); the values are expressed as cells/mm³. Albumin was quantitatively determined by an automated colorimetric
method (Siemens Healthcare Diagnostics Inc., Newark, DE, USA) employing bromocresol purple as a color reagent \(^{29}\), and is expressed as g/dL. Serum CRP was quantified by a nephelometric method (Siemens Dade Behring Inc., Newark, DE, EUA) \(^{30}\) and is expressed as mg/L.

**Nutritional status**

The variation of weight related to the previous study period was assessed by calculating the weight loss percentage, resulting from the division between \(\Delta W\) (the difference between usual weight and current weight) and the usual weight multiplied by 100 \(^{20}\).

Several variables were assessed to evaluate nutritional status. Arm circumference (AC), mid-upper arm circumference (MUAC), and triceps skinfold (TS) (expressed in cm and mm, respectively). Mid-upper arm muscle circumference (MUAMC) was calculated according to the expression: \(\text{MUAC} - (\pi \times \text{TS})/10\). Body mass index (BMI) was calculated by the ratio of weight (kg) to the square of the height (m). The cutoff points for classification were proposed by the World Health Organization \(^{44-46}\). Nutritional Risk Index (NRI) was calculated based on the equation:

\[
1.519 \times \text{serum albumin (g/dL)} + 41.7 \times \frac{\text{current weight (kg)}}{\text{usual weight (kg)}}
\]

The classification adopted was: No nutrition risk: >100; Borderline nutrition risk: 99.9-97.5; Mild nutrition risk: 83.5-97.5; Severe nutritional risk: <83.5 \(^{8,26}\).

The CRP/albumin index was applied to categorize the inflammatory-nutritional prognosis of the patient. Classification adopted was: without risk: <0.4, low risk: 0.4 to 1.2; moderate risk: 1.2 to 2.0; high risk: >2.0 \(^{16}\).

**Plasma fatty acids profile**

The plasma fatty acid profile was determined by High-Performance Liquid Chromatography (HPLC), according to Nishiyama-Naruke et al. \(^{36}\). Plasma fatty acid constituents of phospholipids, triacylglycerols, cholesterol esters, and free fatty acids were extracted using chloroform:methanol (2:1, vol:vol), adapting the method described by Folch et al. \(^{24}\). Lipid extracts were suspended in methanol, and the pH was adjusted to \(\geq 12\) with 5 mol/l NaOH. The aqueous solution was acidified with hydrochloric acid (pH \(\leq 3\)) and subjected to a new lipid extraction using hexane, followed by evaporation in gas \(\text{N}_2\) at 37 °C. Fatty acids were derivatized with 4-bromomethyl-7-coumarin and acetonitrile according to Abushufa, Reed and Weinkove \(^{1}\), and subsequently separated.
on a reversed phase analytical column (Discovery BIO Wide Pore, C8, 5 microns particles, 250 x 4.6 mm (Supelco- Sigma-Aldrich®). The chromatographic analysis was performed with a Waters AllianceBIO Separation Module e2796 (Waters, Milford, MA, USA). Sixteen microliters of derivatized fatty acids were injected and then eluted by the binary gradient of acetonitrile: water from 70:30 to 90:10 at 0.5 mL/min in 80 minutes run at a temperature between 18 to 21°C. The compounds were detected by fluorescence detection (Waters 2475 Multi λ Fluorescence Detector), with excitation at 325 nm and emission at 398 nm. Chromatographic data were recorded and integrated into Empower Pro Version 2.0 software. The following fatty acids were investigated: DHA; EPA; arachidonic; stearic; oleic; linoleic; α-linolenic; palmitic; myristic; lauric. Data are expressed as a percentage of total fatty acids.

**Overall survival, hospital readmissions, and number chemotherapy sessions**

Overall survival (OS) was defined as the time elapsed between baseline (the day of the first chemotherapy) and death from any cause or censored if alive at follow-up date (the follow-up was standardized to 465 days - 15.5 months - after study entry). The date of death, hospital readmissions and the number of chemotherapy sessions were recorded from patient medical records. OS curves were computed using the Kaplan–Meier method and compared using log-rank tests.

**Statistical analysis**

For statistical analyses, the intake of fish oil was considered the exposure variable. Data normality was tested by applying the Shapiro-Wilk test. Student's unpaired t-test or Mann-Whitney test were used to test for differences between groups at each time point. Student’s paired t-test or Wilcoxon test for paired data were used to test the differences between time points within a study group.

All analyses were performed in STATA® 11.0 version for Windows (StataCorp, Texas, USA) and figures were drawn using GraphPad Prism v.5.01 (Graphpad Inc.; La Jolla, USA). P <0.05 was considered to indicate statistical significance.

Two models for statistical analyses were applied: Model 1 included all eligible patients that accepted to participate and finished the nine weeks follow-up; Model 2 included patients from SG that presented ≥ 100% increment in proportions of plasma EPA and DHA at 9 weeks compared to baseline and UG patients who did not show an increment (< 50% increase) in plasma EPA and DHA at 9 weeks when compared to
baseline. Such strategy was applied to reduce any potential heterogeneity related to the absorption and incorporation of fatty acids caused by the chemotherapy.

Results

Eighty-one new cases of hematologic diseases were identified at University Hospital Professor Polydoro Ernani de São Thiago/Federal University of Santa Catarina between November 2012 to December 2013. Fifty patients were not eligible for participation in the study according to the inclusion/exclusion criteria. Therefore, 31 patients were invited to take part in the trial. Three patients chose not to participate. Finally, 28 patients (90.3% of the eligible patients) were randomized to two study groups (model-1). Afterward, according to the analysis of the plasma fatty acid profile, 14 patients were randomized to the same two study groups (model 2), as shown in Figure 1. Six participants were withdrawn from the study, three per group. The reasons for withdrawal are given in figure 1.

In both analysis models, plasma EPA and DHA concentrations did not change in the UG (P>0.05) (Supplementary table 1). In the SG, EPA and DHA increased in the SG in both analysis models. However, the increase in plasma DHA for model 1 reached a P=0.07, which can be interpreted as a statistical tendency (Supplementary table 1).

Characteristics of the study participants

Baseline characteristics of the 22 randomized patients for model 1 and the 14 patients in model 2 did not differ between UG and SG (table 1). Acute leukemia (AL) and Non-Hodgkin lymphoma (NHL) were the main diagnoses in patients included in both analysis models. The distribution of patients between groups according to sex was not different. The concomitant diseases presented by the patients were: osteoporosis, type 2 diabetes mellitus, hypertension, rheumatoid arthritis, depression, gastritis, gastric ulcer, hiatal hernia, esophagitis and hypothyroidism, and hyperthyroidism. Although the percentage of weight loss in the last six months before chemotherapy was numerically higher in the UG compared to the SG, this is statistically significant.

Anthropometric parameters and nutritional status

No significant changes were observed in either analysis model for weight, mid-upper arm circumference (MUAC), triceps skinfold (TS) and mid-upper arm muscle
circumference (MUAMC) (table 2). For model 2, BMI was lower in SG than in UG at the end of the nine weeks (P<0.05). However, NRI was higher in SG than in UG using model 2 (P<0.05) (Table 2).

The CRP/albumin ratio for both models of analysis is shown in figure 2. Both groups had a significant decrease in the inflammatory-nutritional risk from baseline to the ninth week (T1) for analysis model 1. UG patients changed their classification from high to the medium and low risk of complications categories. In the group ingesting fish oil, most patients were categorized as low risk or no risk, after supplementation (UG = 5.1 [2.0; 31.6] to 1.4 [1.0; 9.0]; SG = 12.6 [2.8; 18.1] to 1.1 [0.9; 6.8]; p<0.05). There were no significant differences between groups when analysis model 2 was applied, besides the same changes to a lower risk category (Figure 2).

Blood, serum and plasma parameters

UG showed a significant increase in red blood cell count (RBC) with both analysis models (table 3). Hematocrit and leukocytes increased significantly after nine weeks for model 1 (P<0.05). These changes did not occur in the SG. Additionally, using model 1, the SG had a significant reduction in serum levels of CRP (P<0.05), which did not occur in patients in the UG (table 3).

Overall survival of the patients that completed the study

During the nine weeks of the trial, three patients in the UG died (Figure 1). Patients that completed the nine weeks of the trial were followed for additional 14 months; outcomes were survival (Figure 3), hospital readmissions and the number of chemotherapy cycles. No significant differences were observed in the number of hospital readmissions. However, the number of chemotherapy cycles was significantly higher in the SG independent of the model of analysis (Supplementary Table 2). During the follow-up, four patients of the UG started palliative chemotherapy treatment. In the SG, two patients relapsed after one year of remission and were submitted to further chemotherapy sessions (data not shown).

There were no reported deaths during the 465 days of follow-up for the patients in the SG independent of the analysis model. In contrast, the total number of reported deaths in the UG was eight when analysis model 1 was used (log rank P=0.005 when compared to the SG group) (Figure 3A). Applying model 2 analysis, there were six
reported deaths in the UG (log rank P=0.008 when compared to the SG group) (Figure 3B).

Discussion

This randomized clinical trial showed that ingesting 2 g/day of supplemental fish oil improved long-term survival in patients with hematological malignancies receiving chemotherapy. Furthermore, patients receiving fish oil were also able to undertake a greater number of cycles of chemotherapy. Fish oil containing 367 mg of EPA and 243 mg of DHA for nine weeks was sufficient to alter the fatty acid composition of plasma lipid constituents, leading to a ~2-fold increment in the proportion of EPA and 1.8-fold for DHA. The same has been shown in previous studies (22, 32, 40).

Studies testing EPA and DHA effects in patients diagnosed with hematologic malignancies are scarce. One previous study was performed in early-stage Chronic Lymphocytic Leukemia (21) and another one in acute myeloid leukemia (7). Both used fish oil as a nutritional strategy in parallel with chemotherapy. However, neither of these previous studies assessed the same outcomes assessed in the current study. Hence, it is difficult to compare our findings with the ones of these two previous studies.

In vitro and review studies have concluded that EPA and DHA can induce apoptosis in leukemic cell lineages (14, 25, 48). Furthermore, in vitro studies performed with leukemic cell lines have shown an increment in the antineoplastic action of drugs used in chemotherapy when EPA and DHA are present in the culture medium (22, 47, 18). Additionally, in dogs with Lymphoblastic lymphoma, EPA and DHA ingestion increased survival and decreased plasma IL-6 concentration (37).

RCTs conducted in different types of cancer patients receiving chemotherapy and supplemented with n-3 PUFAs have shown positive effects of this strategy on inflammatory and nutritional outcomes. For example, a double-blind RCT with patients with lung cancer observed increased body weight and a reduction in inflammatory indexes in the group that received fish oil containing 510 mg EPA and 310 mg DHA (23). A RCT testing colorectal cancer patients found that fish oil containing 367 mg EPA and 243 mg DHA, given daily for nine weeks, decreased serum levels of CRP (34), reduced inflammatory and nutritional risk (34, 42), and maintained or increased BMI and body weight during chemotherapy (42).
A systematic review regarding the effects of n-3 PUFA in cancer patients receiving chemotherapy concluded that the main beneficial effect of this supplementation is the preservation of body weight and body composition\(^{(17)}\). However, in our study, there were no significant changes in body weight or BMI with fish oil supplementation. Nevertheless, we observed a trend increment in MUAMC in the subjects supplemented with fish oil, suggesting preservation or gain of lean mass. In addition, NRI was higher in patients receiving fish oil.

Studies with different cancer patients demonstrated a decrease in inflammation after supplementation with n-3 PUFAs\(^{(6, 50, 12, 19)}\). These effects may be partly due to inflammatory and immune response modulation by n-3 PUFAs as a result of an altered pattern of production of lipid mediators including eicosanoids, such as prostaglandins, leukotrienes, thromboxanes, resolvins (E and D), and D1 protectins\(^{(10, 27, 41)}\). Additionally, some n-3 PUFAs anti-inflammatory effects seem to be exerted through the decreased activation of the pro-inflammatory transcription factor NF-\(\kappa\)B and perhaps increased activation of the anti-inflammatory transcription factor peroxisome proliferator activated receptor-gamma (PPAR\(\gamma\))\(^{(9, 43, 11)}\).

In this study, chemotherapy affected the CRP/albumin ratio. In the UG the risk classification changed from high to moderate. However, in patients who received fish oil, the risk classification changed from high to low. This risk classification decline can be an indicative of a positive effect of supplementation with fish oil. The same effect had been shown previously in patients with colorectal cancer\(^{(34, 42)}\). Thus, the CRP/albumin ratio may be a sensitive marker of the ability of fish oil supplementation to improve the inflammatory-nutritional status in these patients.

Survival up to 465 days of follow-up was greater when patients ingested fish oil independent of the model of analysis. Similarly, some previous studies showed prolonged survival after n-3 PUFA supplementation in patients with pancreatic cancer\(^{(31)}\), advanced non-small cell lung cancer\(^{(35)}\), and metastatic breast cancer\(^{(5)}\). The longer survival might be attributed to the effects fish oil in the nutritional-inflammatory risk. Additionally, the increment of the antineoplastic action and reduction of the toxicity of the chemotherapy\(^{(38)}\), could explain such observations.

The data presented here suggest that it will be important for future trials to perform medium or long-term follow-up of some variables relevant to the clinical environment (e.g. survival, hospital readmissions, etc.). Furthermore, it may be possible for researchers involved in previous trials to retrospectively check clinical
variables from the enrolled patients looking for a medium or long-term changes that
were not part of the original follow-up in some trials.

Studies with oral fish oil supplementation have a specific limitation: regular fish
oil’s odor and aftertaste affect the performance of double-blind placebo-controlled
trials. Although some studies try to minimize this limitation using deodorized fish oil
capsules, in medium to low-income countries, regular fish oil is easily assessable when
compared to other forms available in the market. Therefore, no placebo was offered to
the control group. Other limitations include the study sample, which was composed by
patients with different onco-hematological diagnosis, with different disease staging,
chemotherapy regimes, and co-morbidities. However, the cohort was a result of a
careful screening according to our inclusion and exclusion criteria. We believe our
criteria were important to reduce additional confounding factors. Nevertheless, despite
these limitations, the data from the present study provide relevant information to guide
future research in these health conditions.

In conclusion, the ingestion of fish oil concomitant with chemotherapy increases
long-term survival (465 days after the beginning of the chemotherapy) potentially by
reducing the inflammatory-nutritional risk, in patients with hematological malignancies.
Bigger clinical trials, focusing these patients, need to be conducted to test such findings
globally.

Acknowledgments

We are grateful to the Graduate Program in Nutrition – Federal University of Santa
Catarina, Brazil; Fellowship Program Social Demand / Brazilian Federal Agency for
Support and Evaluation of Graduate Education (CAPES); and Phytomare for the
donation of dietary supplements. We thank Professor André Bafica for making the
HPLC equipment facility (funded by Nanobiotec CAPES) available to us.

Financial Support

This research was supported by a grant from the National Counsel of Technological and
Scientific Development (CNPq) – Universal call - CNPq Nº 14/2011 – project
473321/2011-4. CNPq had no role in the design, analysis or writing of this article.
References


500
502
504
506
508
Legends

Figure 1 - Flowchart of patients in the study. Model 1 included all eligible patients that accepted to participate and finished the nine weeks of follow-up. Model 2 included patients from SG that presented ≥ 100% increment in the proportion of plasma EPA and DHA at 9 weeks compared to baseline and UG patients who did not show an increment (< 50%) in plasma EPA and DHA at 9 weeks when compared to baseline.

Figure 2 - CRP/albumin ratio of patients with hematological neoplasms supplemented with fish oil during chemotherapy on different moments: T0 - Data before the first session of chemotherapy; T1 - Data after 9 weeks of chemotherapy. A) Model 1 included all eligible patients that accepted to participate and finished the nine weeks of follow-up; Model 1: UG: Unsupplemented group n=13; SG: Supplemented Group n=9 and, B) Model 2: included patients from SG that presented ≥ 100% increment in the proportion of plasma EPA and DHA at 9 weeks compared to baseline, and UG patients who did not show an increment (< 50%) in plasma EPA and DHA at 9 weeks when compared to baseline. Model 2: UG group n=8; SG n=6. C and D (model 1), E and F (model 2) line representation to visualize individual changes in nine weeks. CRP/albumin ratio: values represent an inflammatory - nutritional risk index. Without risk: <0.4, low risk: 0.4–1.2; moderate risk: 1.2–2.0, high risk: > 2.0. # P value for Wilcoxon test for paired data.

Figure 3 - Overall survival (OS) was defined as the time elapsed between baseline (the day of the first chemotherapy) and death from any cause until 465 days of follow-up. OS curves according to fish oil supplementation were computed using the Kaplan–Meier method and compared using log-rank tests. A) Model 1: US: n=13; SG: _n=9 included all eligible patients that accepted to participate and finished the nine weeks of follow-up. B) Model 2: UG: n=8; SG, n=6 included patients from SG that presented ≥ 100% increment in the proportion of plasma EPA and DHA at 9 weeks compared to baseline and UG patients who did not show an increment (< 50%) in plasma EPA and DHA at 9 weeks when compared to baseline. Abbreviations: UG: Unsupplemented group, SG: Supplemented Group.
**Table 1** - Characteristics of the patients at baseline.

**Table 2** - Nutritional status parameters of patients with hematological malignancies supplemented or not with fish oil during chemotherapy.

**Table 3** - Blood parameters of study’s patients supplemented or not with fish oil during chemotherapy.

**Supplementary Table 1** - Percentage (%) of plasma fatty acids in patients with hematological malignancies supplemented or not with fish oil during chemotherapy.

**Supplementary Table 2** - Number of hospital readmissions and chemotherapy cycles during 465 days of follow-up.